Local Control of Metastatic Lung Tumors Treated with SBRT of 48 Gy in Four Fractions: in Comparison with Primary Lung Cancer

Overview

Journal Jpn J Clin Oncol

Publisher Oxford University Press

Specialty Oncology

Date 2009 Oct 15

PMID 19825814

Citations 19

Authors

Yasushi Hamamoto

Masaaki Kataoka

Motohiro Yamashita

Tetsu Shinkai

Yoshiro Kubo

Yoshifumi Sugawara

Takeshi Inoue

Shinya Sakai

Shoji Aono

Tadaaki Takahashi

Takatoshi Semba

Kotaro Uwatsu

Affiliations

Soon will be listed here.

Abstract

Objective: The optimal dose of stereotactic body radiotherapy (SBRT) for metastatic lung tumors has not been clarified. Local control rates of metastatic lung tumors treated with SBRT of 48 Gy in four fractions, which is one of the common dose schedules for Stage I primary lung cancer in Japan, were examined.

Methods: Between 2006 and 2008, 12 metastatic lung tumors (colorectal cancer, 7; others, 5) in 10 patients and 56 lesions of Stage I primary lung cancer (T1, 43; T2, 13) in 52 patients were treated with SBRT of 48 Gy in four fractions at the isocenter.

Results: Two-year overall survival rates were 86% for patients with metastatic lung tumors and 96% for patients with Stage I primary lung cancer (P = 0.4773). One- and 2-year local control rates were 48% and 25% for metastatic lung tumors, and 91% and 88% for Stage I primary lung cancer, respectively (P < 0.0001).

Conclusions: The local control rates after SBRT of 48 Gy in four fractions were significantly worse in metastatic lung tumors compared with Stage I primary lung cancer. In SBRT, metastatic lung tumors should be clearly differentiated from primary lung cancer and should be given higher doses.

Citing Articles

Interstitial High-Dose-Rate Brachytherapy Combined with External Beam Radiation Therapy for Dose Escalation in the Primary Treatment of Locally Advanced, Non-Resectable Superior Sulcus (Pancoast) Tumors: Results of a Monocentric Retrospective Study.

Neu M, Kahl K, Korner M, Walter R, Raab S, Jehs B J Clin Med. 2025; 13(24.

PMID: 39768473 PMC: 11728414. DOI: 10.3390/jcm13247550.

Comparison of stereotactic body radiotherapy and radiofrequency ablation for early-stage non-small cell lung cancer: a systematic review and meta-analysis.

Zhang R, Kang J, Ren S, Xing L, Xu Y Ann Transl Med. 2022; 10(2):104.

PMID: 35282118 PMC: 8848429. DOI: 10.21037/atm-21-6256.

Local Control After Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer.

Lee P, Loo Jr B, Biswas T, Ding G, El Naqa I, Jackson A Int J Radiat Oncol Biol Phys. 2019; 110(1):160-171.

PMID: 30954520 PMC: 9446070. DOI: 10.1016/j.ijrobp.2019.03.045.

A matched-pair analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer versus early stage non-small cell lung cancer.

Wang X, Zamdborg L, Ye H, Grills I, Yan D BMC Cancer. 2018; 18(1):962.

PMID: 30305131 PMC: 6180414. DOI: 10.1186/s12885-018-4865-9.

Stereotactic Radiotherapy for Pulmonary Oligometastases From Colorectal Cancer: A Systematic Review and Meta-Analysis.

Jingu K, Matsushita H, Yamamoto T, Umezawa R, Ishikawa Y, Takahashi N Technol Cancer Res Treat. 2018; 17:1533033818794936.

PMID: 30145943 PMC: 6111389. DOI: 10.1177/1533033818794936.